European shares fall as Middle East tensions weigh; eyes on Fed decision

European shares declined 0.4% on Wednesday, nearing a one-month low, as investors awaited the Federal Reserve's monetary policy decision amid escalating Middle East tensions; defense stocks were an exception, gaining 0.6%. The Swedish central bank cut its key interest rate to 2.00% from 2.25%, while the Bank of England is expected to hold rates steady, and Novo Nordisk shares fell 1% after a U.S. judge upheld the FDA's decision to remove Ozempic and Wegovy from the drug shortage list.

Analysis

European equity markets, exemplified by the pan-European STOXX 600 index closing down 0.4% to a near one-month low, experienced a downturn driven by investor apprehension ahead of the Federal Reserve's monetary policy announcement and heightened geopolitical instability stemming from ongoing Iran-Israel hostilities, now in their sixth day. This risk-off sentiment was underscored by fears of direct U.S. involvement following President Donald Trump's call for Iran's unconditional surrender, a demand rejected by Iranian Supreme Leader Ayatollah Ali Khamenei. Conversely, defence stocks registered gains, with the sector appreciating 0.6%, reflecting a flight to perceived safety. Market participants are keenly awaiting the Federal Reserve's statements at 1800 GMT, where interest rates are widely anticipated to remain unchanged, but guidance on navigating an uncertain trade environment and potential inflation risks from the Middle East crisis will be critical, as highlighted by Swissquote Bank's senior analyst Ipek Ozkardeskaya who noted that "Rising geopolitical and trade uncertainties mean the Fed’s growth and inflation forecasts may lack precision." Concurrently, European Commission President Ursula von der Leyen is aiming to secure a trade deal with Washington by July 9, amidst the approaching July 8 tariff-pause deadline, though only a U.S.-UK agreement has been finalized. National bourses showed mixed performance: London’s FTSE 100 edged up 0.1% following expected easing in May's British inflation, though the Bank of England is projected to maintain current rates as services inflation remains elevated. Sweden’s central bank implemented an anticipated rate cut from 2.25% to 2.00%, yet Stockholm’s benchmark index declined 0.1%. The healthcare sector exerted significant downward pressure on the STOXX 600, notably with Novo Nordisk shares falling 1% after a U.S. judge upheld the FDA's decision to remove Ozempic and Wegovy from its drug shortage list. Despite current headwinds, Barclays maintains an optimistic year-end 2026 target of 620 for the STOXX 600, citing German stimulus and rate cuts as potential drivers. Company-specific news also created volatility, with French outsourcing firm TP plummeting 13.6% after announcing new medium-term targets, while German medical packaging maker Gerresheimer surged 6.3% on news of KPS Capital Partners' continued talks with Warburg Pincus regarding a potential joint takeover bid.

Key Decisions for Investors

• Investors should exercise caution and closely monitor the Federal Reserve's upcoming commentary for signals on future monetary policy and its assessment of trade and geopolitical risks.
• Consider defensive portfolio adjustments, such as exposure to the outperforming defence sector, while remaining vigilant to company-specific developments like those impacting Novo Nordisk, TP, and Gerresheimer.
• Evaluate the implications of diverging central bank policies, such as Sweden's rate cut versus anticipated holds from the Fed and Bank of England, for currency and fixed-income strategies, and track the progress of US-EU trade negotiations given the approaching deadlines.